Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of BT200 in Healthy Volunteers
NCT04103034Phase 1Completed
- Sponsor
- Band Therapeutics LLC
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rondaptivon pegol in cerebrovascular accident (CVA), large artery atherosclerosis (LAA) and intracranial atherosclerosis (ICAD), sponsored by Band Therapeutics LLC. Primary endpoint: Number of Participants With Treatment-related Adverse Events at 8 weeks. Started Oct 2019; status: completed.
02
Drugs
rondaptivon pegol
03
Conditions
cerebrovascular accident (CVA)large artery atherosclerosis (LAA)intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT04103034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103034.